- Home
- LXEO vs PEBK Comparison
LXEO vs PEBK Comparison
Compare LXEO & PEBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEO
- PEBK
- Stock Information
- Founded
- LXEO 2017
- PEBK 1912
- Country
- LXEO United States
- PEBK United States
- Employees
- LXEO 72
- PEBK N/A
- Industry
- LXEO
- PEBK Major Banks
- Sector
- LXEO
- PEBK Finance
- Exchange
- LXEO Nasdaq
- PEBK Nasdaq
- Market Cap
- LXEO 154.0M
- PEBK 141.6M
- IPO Year
- LXEO 2023
- PEBK N/A
- Fundamental
- Price
- LXEO $2.69
- PEBK $28.45
- Analyst Decision
- LXEO Strong Buy
- PEBK
- Analyst Count
- LXEO 5
- PEBK 0
- Target Price
- LXEO $22.20
- PEBK N/A
- AVG Volume (30 Days)
- LXEO 892.8K
- PEBK 6.3K
- Earning Date
- LXEO 05-20-2025
- PEBK 04-21-2025
- Dividend Yield
- LXEO N/A
- PEBK 3.20%
- EPS Growth
- LXEO N/A
- PEBK 4.04
- EPS
- LXEO N/A
- PEBK 3.05
- Revenue
- LXEO N/A
- PEBK $83,033,000.00
- Revenue This Year
- LXEO N/A
- PEBK N/A
- Revenue Next Year
- LXEO N/A
- PEBK N/A
- P/E Ratio
- LXEO N/A
- PEBK $9.38
- Revenue Growth
- LXEO N/A
- PEBK 7.01
- 52 Week Low
- LXEO $1.45
- PEBK $23.74
- 52 Week High
- LXEO $19.50
- PEBK $33.31
- Technical
- Relative Strength Index (RSI)
- LXEO 41.96
- PEBK 58.36
- Support Level
- LXEO $2.77
- PEBK $26.87
- Resistance Level
- LXEO $3.35
- PEBK $28.60
- Average True Range (ATR)
- LXEO 0.62
- PEBK 0.76
- MACD
- LXEO -0.09
- PEBK 0.22
- Stochastic Oscillator
- LXEO 0.69
- PEBK 79.04
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About PEBK Peoples Bancorp of North Carolina Inc.
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.